MediPurpose® Announces U.S. Distribution Agreement With Pharmaplast, Egyptian Advanced Wound Care OEM

Agreement is First for MediPurpose's New Wound Care Division

News provided by

Jun 22, 2010, 01:56 ET

ALEXANDRIA, Egypt and NORCROSS, Ga., June 22 /PRNewswire/ -- MediPurpose®, a medical device innovation and medical product distribution company, today announced that it has signed an exclusive agreement to distribute advanced wound care products from Egypt-based OEM Pharmaplast.

The milestone agreement is the foundation for MediPurpose's recently launched Wound Care division. For Pharmaplast, it enables access to an expanded market for its products within the Americas while continuing to expand their worldwide presence.

"We are very pleased to announce our exclusive partnership with Pharmaplast," said MediPurpose COO and President Randy Prather, who oversees the Wound Care division. "Their quality and breadth of product line of advanced wound care products is the ideal foundation for our Wound Care division."

The new Wound Care division—and the subsequent agreement with Pharmaplast— spotlights MediPurpose's attention on new business development to expand medical product lines that complement their award-winning medical product distribution services and logistics capabilities.

"Our distribution services capability was a key advantage that MediPurpose was able to offer that cemented the relationship with our new OEM partner," said Prather. "MediPurpose's goal was to provide a quality, comprehensive advanced wound care line that would afford substantial profit opportunities for our existing and new distribution partners who service this market. Pharmaplast provided us the opportunity to meet and exceed those original goals."

"Additionally, with the launch of this new division, we are very excited about the opportunities to expand the division's product capabilities by partnering with additional wound care products manufacturers that offer complementary products in the Americas and abroad."

MediPurpose founder and CEO Patrick Yi added, "It is our responsibility to ensure that all our new medical product lines achieve the same superior product quality and customer service as our current SurgiLance® safety lancet product line. After an exhaustive evaluation, I am confident that our customers will receive the same standard of service from Pharmaplast."

About Pharmaplast

Started in 1985 by three pharmacists, Pharmaplast engages in the manufacture of advanced wound care and immobilization products.

Today, Pharmaplast is a shareholding company with five factories in Egypt that employ 700 employees. All factories are ISO 9001 certified, all products bear the CE mark and most of the products are FDA registered.

Pharmaplast believes that consistent innovation and quality assurance is the key to its survival, and thus invests to generate new products that help medical professionals to provide quality patient care with maximum cost-efficiency.

For more information about Pharmaplast, please visit http://www.pharmaplast-online.com.

About MediPurpose

Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.

Known for its innovation of the SurgiLance® Safety Lancet, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor.

MediPurpose also offers angel funding, medical product development and medical device consulting for medical device inventors and medical product companies seeking entrance or expansion into the medical device markets.

For more information about MediPurpose's medical products, medical distribution channel management services and medical device development services, please visit http://www.medipurpose.com.

SOURCE MediPurpose